1039phealth Economic Analysis of the Randomized Multicenter Phase Ii Trial Sakk 77/08: Sorafenib with or without Everolimus in Patients with Unresectable Hepatocellular Carcinoma (hcc).

@article{MatterWalstra20141039phealthEA,
  title={1039phealth Economic Analysis of the Randomized Multicenter Phase Ii Trial Sakk 77/08: Sorafenib with or without Everolimus in Patients with Unresectable Hepatocellular Carcinoma (hcc).},
  author={K Matter-Walstra and Matthias Schwenkglenks and Qiyu Li and I Cvijetic and Britta Tschanz and Panagiotis Samaras and Piercarlo Saletti and Arnaud D. Roth and Daniel Horber and Dieter Koeberle},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2014},
  volume={25 suppl_4},
  pages={iv358}
}
K. Matter-Walstra1, M. Schwenkglenks1, Q. Li2, I. Cvijetic3, B. Tschanz3, P. Samaras4, P. Saletti5, A.D. Roth6, D. Horber7, D. Koeberle7 Institute of Pharmaceutical Medicine, University Basel, Basel, SWITZERLAND Statistics, SAKK, Bern, SWITZERLAND Clinical Trial Management, SAKK, Bern, SWITZERLAND Inner Medicine, University Hospital Zürich, Zürich… CONTINUE READING